RITUXIMAB IN THE TREATMENT OF INDOLENT NON-HODGKIN’S LYMPHOMA

Autori:

IGOR AURER, ZDRAVKO MITROVIĆ, IVO RADMAN, JASMINKA KOVAČEVIĆ-METELKO, DAMIR NEMET, RANKA SERVENTI-SEIWERTH, RANKA ŠTERN-PADOVAN, JASMINKA JAKIĆ-RAZUMOVIĆ, MARIN NOLA, SILVA ZUPANČIĆ-ŠALEK, DUBRAVKA SERTIĆ, BORIS LABAR

Sažetak
Indolentni nehodgkinovi limfomi (NHL) skupina su neoplazmi imunosnog sustava, koje sporo napreduju i ne mogu se izliječiti konvencionalnim liječenjem. Rituksimab je monoklonsko protutijelo usmjereno protiv antigena CD20. Ovaj lijek se sve više rabi u liječenju B-staničnih limfoidnih neoplazma. Ovdje prikazujemo svoja iskustva u 25 bolesnika s indolentnim NHL-om liječenih rituksimabom s kemoterapijom ili bez nje. Bolesnici su rituksimab primali u dozi od 375 mg/m2 svaka tri do četiri tjedna. Na terapiju je odgovorilo 88% bolesnika: 16 je postiglo kompletnu, a 6 parcijalnu remisiju. Dvogodišnje preživljenje iznosi 63%. Bolesnici s povoljnijim prognostičkim značajkama imaju značajno bolji odgovor i preživljenje. Nuspojave su zabilježene u 2 bolesnika i bile su blage. Naši su rezultati sukladni podacima iz literature i pokazuju da je rituksimab djelotvoran i neškodljiv lijek za liječenje indolentnih NHL B-imunofenotipa.
Summary

Summary. Indolent Non-Hodgkin’s lymphomas (NHL) are a group of slowly progressive immune system malignancies that cannot be cured with conventional treatment. Rituximab is an anti-CD20 monoclonal antibody that has recently become a part of the standard treatment of B-cell lymphoid malignancies. Here we present our experience in 25 patients with indolent NHL treated with rituximab with or without chemotherapy. Rituximab was administered at 3–4 week intervals in the standard dose of 375 mg/m2. 88% of the patients responded, 16 achieved a complete and 6 partial remission. Estimated 2-year actuarial survival is 63%. Response and survival rates were significantly better in patients with favorable prognosis (lower IPI score). Adverse effects related to rituximab occurred in 2 patients and were mild. Our results are completely comparable to previously reported studies and show that rituximab is effective and safe for the treatment of indolent B-cell NHL.

Volumen: 11-12, 2004

Liječ Vjesn 2004;126:307–311

Boris Labar, Damir Nemet, Dubravka Sertić, Igor Aurer, Ivo Radman, Jasminka Jakić-Razumović, Jasminka Kovačević-Metelko, Marin Nola, Ranka Serventi-Seiwerth, Ranka Štern-Padovan, Silva Zupančić-Šalek, Zdravko Mitrović

Preuzmi PDF